Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued on Monday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reduced their price objective on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.

Aethlon Medical Price Performance

AEMD stock opened at $1.28 on Monday. The company has a fifty day moving average price of $1.59 and a two-hundred day moving average price of $1.75. Aethlon Medical has a one year low of $1.28 and a one year high of $5.00. The stock has a market cap of $3.35 million, a price-to-earnings ratio of -0.26 and a beta of 1.95.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). Research analysts anticipate that Aethlon Medical will post -4.98 EPS for the current fiscal year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.